USANA Health Sciences, Inc. (NYSE:USNA) Director Peggie Pelosi Sells 780 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Peggie Pelosi sold 780 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $28.10, for a total value of $21,918.00. Following the sale, the director now directly owns 3,395 shares in the company, valued at approximately $95,399.50. This trade represents a 18.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

USANA Health Sciences Stock Up 1.3 %

NYSE:USNA opened at $29.97 on Tuesday. The stock’s 50-day simple moving average is $33.42 and its 200 day simple moving average is $36.47. The firm has a market capitalization of $571.21 million, a PE ratio of 10.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. USANA Health Sciences, Inc. has a twelve month low of $27.71 and a twelve month high of $50.32.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

USNA has been the topic of several analyst reports. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently bought and sold shares of the company. Barclays PLC raised its position in USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after purchasing an additional 14,647 shares during the last quarter. Geode Capital Management LLC raised its position in USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after purchasing an additional 12,898 shares during the last quarter. State Street Corp raised its position in USANA Health Sciences by 0.6% in the third quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after purchasing an additional 2,782 shares during the last quarter. Nordea Investment Management AB raised its position in USANA Health Sciences by 5.7% in the fourth quarter. Nordea Investment Management AB now owns 50,450 shares of the company’s stock valued at $1,814,000 after purchasing an additional 2,723 shares during the last quarter. Finally, Pacer Advisors Inc. raised its position in USANA Health Sciences by 8.8% in the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock valued at $21,247,000 after purchasing an additional 47,745 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.